It is not a high growth company any more.
CAD down to 19 cents, in the past they paid off 75% of the cad. The only britght spot is IRT, we will see the report tomorrow.
by 2020, I will be surprised this company will still be independent in two months.
especially for those who used the drug first time, this is a multi billion dollar industry, for the 27% effective rate is extremely impressive, the market value is only 40 million, give me a break. It is heading to double digits.
Citi was doing a horrible job for pricing the secondary, they should do it in the middle of trading today.
I hope they don't price at $15 tomorrow.
1.3 billion is simply too big. I am hoping they raised some money and borrow some, at the same time, also hope interest will not go up too much before they could lock in the deal.
sounds like a secondary very soon, the big guy got the information first.
are two issues facing NRZ now, otherwise, the fundamental is still loooking pretty good.
Any one could explain, the does OCN issue will have any impact on NRZ in the future?